Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront
(RTTNews) – Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) to co-develop and co-commercialise Bexobrutideg, following expiration of the waiting period under the Hart-Cottrell-Rodino Antitrust Improvements Act of 1976. Bexobrutideg (NX-5948) is an investigational, orally bioavailable small-molecule degrader of Bruton’s […]